Compare Merck & Co., Inc. (MRK) vs Zoom Video Communications, Inc. (ZM) Price & Performance

Merck & Co., Inc.Trade

Zoom Video Communications, Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Zoom Video Communications, Inc. — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Zoom Video Communications, Inc. trades at $89.99 (market cap $26.66B). The key difference: Merck & Co., Inc. is far larger — about 11.5× Zoom Video Communications, Inc.'s market cap, and Merck & Co., Inc. pays a 2.73% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.

	MRK	ZM
Market Cap	$307.25B	$26.66B
Sector	Health	Technology
52-Week High	$129.52	$111.88
52-Week Low	$77.60	$69.77
Enterprise Value	$350.66B	$19.00B
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Zoom Video Communications, Inc.

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 8 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

Zoom appoints Carlos Quaderi as Head of APAC to lead AI-driven growth phaseHayley Yap · 12 hours agoBullish Zoom names Carlos Quaderi Head of APAC to boost AI-driven growth and expand regional market reach.GlobeNewsWire · 1 day agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Zoom Video Communications, Inc.

Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.